Table 4
Time specific relative risks of non-fatal ischaemic heart disease and cardiac failure
| Month and event | Patients (n) | Unadjusted relative risks (95% CL) | Age and sex adjusted relative risks (95% CL) |
|---|---|---|---|
| Cardiac failure | |||
| Month 1 | |||
| Nedocromil4-150 | 6 | 1 | 1 |
| Salmeterol | 10 | 1.23 (0.45 to 3.40) | 0.81 (0.29 to 2.25) |
| Bambuterol | 31 | 8.41 (3.51 to 20.15)§ | 4.41 (1.90 to 10.27)§ |
| Months 2–6 | |||
| Nedocromil4-150 | 12 | 1 | 1 |
| Salmeterol | 35 | 1.67 (0.85 to 3.14) | 1.25 (0.64 to 2.44) |
| Bambuterol | 33 | 5.34 (2.76 to 10.33)§ | 2.67 (1.30 to 5.47)† |
| Ischaemic heart disease | |||
| Month 1 | |||
| Nedocromil4-150 | 5 | 1 | 1 |
| Salmeterol | 12 | 1.78 (0.63 to 5.04) | 1.32 (0.46 to 3.78) |
| Bambuterol | 14 | 4.55 (1.64 to 12.63)‡ | 3.95 (1.38 to 11.31)† |
| Months 2–6 | |||
| Nedocromil4-150 | 24 | 1 | 1 |
| Salmeterol | 54 | 1.26 (0.78 to 2.03) | 1.01 (0.62 to 1.63) |
| Bambuterol | 12 | 0.96 (0.48 to 1.93) | 0.67 (0.34 to 1.34) |
-
↵4-150 Reference drug; †p<0.01; ‡p=0.001; §p<0.0001.
